
Hantavirus vaccines edge closer, but rollout remains years away
Hantavirus currently has no cure and treatment is supportive. Global researchers are developing vaccines (including EnsiliTech and Moderna) targeting American strains; animal studies show promise, but human trials and regulatory approval will take years. The recent outbreak on a luxury cruise underscored its lethality, with mortality up to ~40% for hantavirus pulmonary syndrome and 1–12% for hemorrhagic fever with renal syndrome. Canada has logged 168 cases since 1994. If funding and political will align, a vaccine could reach high-risk groups within several years (roughly 3–4) after successful trials.













